KORU Medical Systems Gelecekteki Büyüme

Future kriter kontrolleri 1/6

KORU Medical Systems kazanç ve gelirinin sırasıyla yıllık 67.4% ve 14.7% oranında artması tahmin edilirken, EPS'nin yıllık 68% oranında büyümesi bekleniyor.

Anahtar bilgiler

67.4%

Kazanç büyüme oranı

68.0%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	17.0%
Gelir büyüme oranı	14.7%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	09 Dec 2024

Gelecekteki son büyüme güncellemeleri

KORU Medical Systems, Inc. (NASDAQ:KRMD) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.10

Nov 16

Recent updates

KORU Medical Systems, Inc. (NASDAQ:KRMD) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.10

Nov 16

Impressive Turnaround At KORU Medical

Nov 06

We're Interested To See How KORU Medical Systems (NASDAQ:KRMD) Uses Its Cash Hoard To Grow

Aug 29

Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Earnings Pushing Shares 28% Lower

Jul 14

We're Not Very Worried About KORU Medical Systems' (NASDAQ:KRMD) Cash Burn Rate

Sep 27

Repro Med Systems (NASDAQ:KRMD) Is In A Good Position To Deliver On Growth Plans

Oct 27

Analysts Have Been Trimming Their Repro Med Systems, Inc. (NASDAQ:KRMD) Price Target After Its Latest Report

Aug 14

Is Repro Med Systems, Inc.'s (NASDAQ:KRMD) Shareholder Ownership Skewed Towards Insiders?

Feb 22

Returns On Capital At Repro Med Systems (NASDAQ:KRMD) Paint An Interesting Picture

Jan 27

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:KRMD - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	44	-1	0	1	3
12/31/2025	38	-4	-1	0	5
12/31/2024	33	-6	-3	-1	5
9/30/2024	32	-12	-2	0	N/A
6/30/2024	31	-12	-1	0	N/A
3/31/2024	29	-13	-1	-1	N/A
12/31/2023	29	-14	-6	-5	N/A
9/30/2023	29	-8	-5	-5	N/A
6/30/2023	29	-8	-7	-6	N/A
3/31/2023	29	-9	-11	-8	N/A
12/31/2022	28	-9	-8	-5	N/A
9/30/2022	27	-8	-10	-7	N/A
6/30/2022	25	-8	-8	-6	N/A
3/31/2022	24	-6	-4	-3	N/A
12/31/2021	23	-5	-5	-4	N/A
9/30/2021	21	-4	-6	-5	N/A
6/30/2021	21	-3	-7	-6	N/A
3/31/2021	23	-3	-4	-4	N/A
12/31/2020	24	-1	-2	-1	N/A
9/30/2020	26	0	1	2	N/A
6/30/2020	27	0	4	5	N/A
3/31/2020	25	1	1	2	N/A
12/31/2019	23	1	0	0	N/A
9/30/2019	21	0	-1	0	N/A
6/30/2019	19	0	-1	-1	N/A
3/31/2019	18	0	0	0	N/A
12/31/2018	17	1	1	1	N/A
9/30/2018	18	2	2	2	N/A
6/30/2018	17	2	N/A	2	N/A
3/31/2018	16	1	N/A	1	N/A
12/31/2017	16	1	N/A	1	N/A
2/28/2017	12	-1	N/A	0	N/A
11/30/2016	13	0	N/A	1	N/A
8/31/2016	13	0	N/A	1	N/A
5/31/2016	13	1	N/A	2	N/A
2/29/2016	12	1	N/A	2	N/A
11/30/2015	12	1	N/A	1	N/A
8/31/2015	12	1	N/A	1	N/A
5/31/2015	11	1	N/A	1	N/A
2/28/2015	11	1	N/A	1	N/A
11/30/2014	10	1	N/A	1	N/A
8/31/2014	10	1	N/A	1	N/A
5/31/2014	9	1	N/A	1	N/A
2/28/2014	9	1	N/A	1	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: KRMD önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: KRMD önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: KRMD önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: KRMD şirketinin gelirinin (yıllık 14.7% ) US pazarından (yıllık 9.1% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: KRMD şirketinin gelirinin (yıllık 14.7% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: KRMD 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/23 03:45
Gün Sonu Hisse Fiyatı	2024/12/23 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

KORU Medical Systems, Inc. 11 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Neil Chatterji	B. Riley Securities, Inc.
Kyle Bauser	B. Riley Securities, Inc.
Kyle Rose	Canaccord Genuity

KORU Medical Systems Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

KORU Medical Systems, Inc. (NASDAQ:KRMD) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.10

Price target increased by 17% to US$4.10

KORU Medical Systems, Inc. Raises Earnings Guidance for the Full Year 2024

Consensus estimates of losses per share improve by 20%

KORU Medical Systems, Inc. Revises Revenue Guidance for the Full Year 2024

Consensus EPS estimates fall by 15%

Recent updates

KORU Medical Systems, Inc. (NASDAQ:KRMD) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.10

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target increased by 17% to US$4.10

KORU Medical Systems, Inc. Raises Earnings Guidance for the Full Year 2024

Impressive Turnaround At KORU Medical

KORU Medical Systems, Inc. to Report Q3, 2024 Results on Nov 13, 2024

We're Interested To See How KORU Medical Systems (NASDAQ:KRMD) Uses Its Cash Hoard To Grow

Consensus estimates of losses per share improve by 20%

New minor risk - Market cap size

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

KORU Medical Systems, Inc. Revises Revenue Guidance for the Full Year 2024

KORU Medical Systems, Inc. (NASDAQ:KRMD) Doing What It Can To Lift Shares

KORU Medical Systems, Inc Announces Executive Changes

KORU Medical Systems, Inc. to Report Q2, 2024 Results on Aug 07, 2024

KORU Medical Systems, Inc.(NasdaqCM:KRMD) dropped from Russell Small Cap Comp Growth Index

KORU Medical Systems Receives Regulatory Clearance for FreedomEdge Infusion System in Japan

KORU Medical Systems, Inc. Announces Collaboration with Global Pharmaceutical Company to Initiate Feasibility Study with Its Freedom Infusion System for FDA and EMA Approved Subcutaneous Oncology Biologic Drug

Consensus EPS estimates fall by 15%

KORU Medical Systems, Inc. reaffirms Financial Guidance for the Full Year of 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

KORU Medical Systems, Inc. Reaffirmes Financial Guidance for the Full Year of 2024

KORU Medical Systems, Inc. to Report Q1, 2024 Results on May 01, 2024

KORU Medical Systems, Inc., Annual General Meeting, May 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

KORU Medical Systems, Inc. Provides Earnings Guidance for the Full Year 2024

KORU Medical Systems, Inc. Announces A Feasibility Study to Enter Ambulatory Infusion Settings with A Commercialized Biologic

KORU Medical Systems, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Revenues

Consensus EPS estimates upgraded to US$0.18 loss, revenue downgraded

Koru Medical Systems, Inc. Appoints Kenneth Miller as Chief Commercial Officer

New minor risk - Market cap size

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60 Infusion System With Hizentra 50 ML Prefilled Syringes

KORU Medical Systems, Inc. to Report Q3, 2023 Results on Nov 08, 2023

High number of new directors

We're Hopeful That KORU Medical Systems (NASDAQ:KRMD) Will Use Its Cash Wisely

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

KORU Medical Systems, Inc. Updates Revenue Guidance for the Full Year 2023

Price target decreased by 10% to US$4.33

KORU Medical Systems, Inc. Provides Revenue Guidance for the Full Year 2023

KORU Medical Systems, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Earnings Pushing Shares 28% Lower

KORU Medical Systems, Inc. Announces 510(K) Submission for Freedom60®? Infusion System with Hizentra®? 50 Ml Preilled Syringes

KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

KORU Medical Systems, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$4.83

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

KORU Medical Revised Revenue Guidance for the Full Year of 2022

KORU Medical Systems, Inc. to Report Q3, 2022 Results on Nov 09, 2022

We're Not Very Worried About KORU Medical Systems' (NASDAQ:KRMD) Cash Burn Rate

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

KORU Medical Systems, Inc. Revises Earnings Guidance for the Full Year 2022

KORU Medical Systems, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Repro Med Systems, Inc. Announces Chief Financial Officer Changes

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

KORU Medical Systems Revises Earnings Guidance for the Year 2022

Price target decreased to US$4.67

Repro Med Systems, Inc. to Report Q1, 2022 Results on May 04, 2022

Repro Med Systems, Inc. Appoints Brian Case as Chief Technology Officer

Consensus forecasts updated

Repro Med Systems, Inc. Provides Revenue Guidance for the Fiscal Year 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Repro Med Systems, Inc. to Report Q4, 2021 Results on Mar 02, 2022

KORU Medical Systems Receives FDA 510(k) Clearance for the Use of the FREEDOM60® with Two Additional SCIg Drugs

Third quarter 2021 earnings released: US$0.025 loss per share (vs US$0.006 profit in 3Q 2020)

Price target decreased to US$4.67

Repro Med Systems (NASDAQ:KRMD) Is In A Good Position To Deliver On Growth Plans